ArticleArthritis research & therapy2026
Elevated sST2 associates with cardiac involvement and declines after treatment in newly diagnosed patients with idiopathic inflammatory myopathies.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCardiac involvement (CI) is a major determinant of poor prognosis in idiopathic inflammatory myopathies (IIM). Soluble suppression of tumorigenicity 2 (sST2) is a biomarker linked to cardiac inflammation and remodelling, but its role has scarcely been explored in IIM. We aimed to investigate the levels of sST2 and its longitudinal profile in patients with IIM and CI.
methodsSerum sST2 levels were measured longitudinally over the course of two years in 34 patients with newly diagnosed IIM and in 109 patients with established IIM from a cross-sectional cohort, as well as in age and gender matched healthy controls (HC) and in patients with rheumatoid arthritis (RA). CI was assessed using cardiac magnetic resonance (CMR) in newly diagnosed IIM patients. Associations between sST2 and clinical parameters were analyzed.
resultsPatients with newly diagnosed IIM exhibited significantly higher sST2 levels at diagnosis compared to HC (P < 0.0001) and patients with established IIM (P < 0.0001). sST2 levels were highest at diagnosis, decreased significantly by 6 months, and remained lower during follow-up. sST2 levels were positively associated with cardiac troponin I and N-terminal pro-brain natriuretic peptide (P = 0.0001 and P = 0.0001, respectively). Importantly, IIM patients with active CMR-verified CI exhibited significantly higher sST2 levels than those without ongoing CI. In contrast, patients with established IIM had sST2 levels comparable to HC and RA patients.
conclusionsST2 is elevated in early IIM and closely associated with cardiac biomarkers and CMR-verified cardiac inflammation. Its dynamic decline with treatment suggests potential utility as a biomarker for early detection and monitoring of CI in IIM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.